L 778123

Drug Profile

L 778123

Latest Information Update: 30 Nov 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Therapy and Research Center; Memorial Sloan-Kettering Cancer Center; Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Nov 2004 Discontinued - Phase-II for Solid tumours in USA (Infusion)
  • 01 May 2002 A phase I study has been added to the Cancer adverse events and pharmacokinetics sections
  • 17 Sep 2001 Phase-II clinical trials for Solid tumours in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top